It has been confirmed that the TIDE score predicts the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 antibodies more accurately than other biomarkers, such as PD-L1 level and mutation load (Jiang et al., 2018). The gene discussed is CD274; the disease is melanoma.